<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589326</url>
  </required_header>
  <id_info>
    <org_study_id>Ponatinib-3001</org_study_id>
    <secondary_id>2018-000397-30</secondary_id>
    <secondary_id>U1111-1206-2370</secondary_id>
    <secondary_id>HC6-24-c220300</secondary_id>
    <nct_id>NCT03589326</nct_id>
  </id_info>
  <brief_title>An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL</brief_title>
  <official_title>A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of ponatinib versus imatinib,
      administered as first-line therapy in combination with reduced-intensity chemotherapy, in
      participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease
      (MRD)-negative complete remission (CR) at the end of induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called ponatinib. Ponatinib is being tested to treat
      people who have newly diagnosed Ph+ ALL. This study will look at the efficacy of ponatinib in
      participants in addition to standard care.

      The study will enroll approximately 230-320 participants. Participants will be randomized in
      a 2:1 ratio to receive oral ponatinib or imatinib (Cohort A and Cohort B, respectively) daily
      throughout the study.

      All participants will be asked to take ponatinib or imatinib at the same time each day with
      reduced-intensity chemotherapy in induction phase (Cycles 1 to 3), consolidation phase
      (Cycles 4 to 9) and maintenance phase (Cycles 10 to 20). At the end of the 20 cycles,
      participants will remain on ponatinib or imatinib (administered as a single agent). The dose
      of ponatinib in consolidation and maintenance phase will start with the last dose given in
      the previous phase. The dose can be modified based on MRD-negative CR results.

      This multi-center trial will be conducted in Argentina, Australia, Austria, Belarus, Brazil,
      Bulgaria, Canada, Chile, France, Mexico, Greece, Italy, Japan, Korea, Republic Of, Poland,
      Romania, Russia, Spain, Taiwan, Province Of China, Turkey, Finland and the United States.
      Participants including those who achieve a clinical response, may receive study drug until
      they are deceased, have failed to achieve the primary endpoint, have experienced relapse from
      CR or have progressive disease, have an unacceptable toxicity, have withdrawn consent, have
      proceeded to HSCT, or until the sponsor terminates the study, whichever occurs first. After
      disease progression, all participants will be contacted every 3 months for survival
      follow-up. Participants will be followed until completion of the study or until the
      participant's death has been reported.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>It is an open-label trial, therefore investigators and participants are unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Minimal Residual Disease (MRD)-Negative Complete Remission (CR)</measure>
    <time_frame>From Cycle 1 through Cycle 3 (approximately 3 months) (Cycle length is equal to [=] 28 days)</time_frame>
    <description>MRD-negative CR is achieved when a participant meets the criteria for both MRD negativity and CR. MRD-negativity: less than or equal to (&lt;=) 0.01 percent (%) breakpoint cluster region-Abelson (BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in complementary deoxyribonucleic acid (cDNA) with greater than or equal to (&gt;=) 10,000 ABL1 transcripts. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and less than (&lt;) 5% blasts in the bone marrow (BM). 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (central nervous system [CNS] involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. Absolute neutrophil count (ANC) greater than (&gt;) 1000 per micro liter (/mcL) (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
    <description>EFS is defined as the dates of randomization until death due to any cause or failure to achieve MRD-negative CR by end of induction or relapse from CR. MRD-negativity: &lt;=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts relapse from CR: reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR and Incomplete Complete Remission (CRi)</measure>
    <time_frame>End of Cycle 1 (approximately 1 month), Cycle 2 (approximately 2 months), Cycle 3 (approximately 3 months), and Cycle 9 (approximately 9 months) (Cycle length= 28 days)</time_frame>
    <description>CR is defined as meeting all the following for at least 4 weeks (that is, no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). CRi is defined as hematologic complete remission with incomplete hematologic recovery and meeting all criteria for CR except platelet count and/or ANC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Molecular Response</measure>
    <time_frame>End of Cycle 1 (approximately 1 month), Cycle 2 (approximately 2 months), Cycle 3 (approximately 3 months), and Cycle 9 (approximately 9 months) (Cycle length= 28 days)</time_frame>
    <description>Molecule response is assessed by 3-Log Reduction (MR3), Molecular Response 4-Log Reduction (MR4) and Molecular Response 4.5-Log Reduction (MR4.5). MR3 is defined as molecular response 3-log reduction (&lt;=0.1% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=1000 ABL1 transcripts. MR4 is defined as molecular response 4-log reduction (&lt;=0.01% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. MR4.5 is defined as Molecular response 4.5-log reduction (&lt;=0.0032% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=32,000 ABL1 transcripts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Primary Induction Failure (PIF)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>PIF is defined as participants who received treatment for ALL but never achieved CR or CRi by the end of induction. PIF is not limited by the number of unsuccessful treatments; this disease status only applies to recipients who have never been in CR or CRi. CR is defined as meeting all the following for at least 4 weeks (that is no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). CRi is defined as hematologic complete remission with incomplete hematologic recovery and meeting all criteria for CR except platelet count and/or ANC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Overall Response Rate (ORR)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>ORR is defined as CR + CRi. CR is defined as meeting all the following for at least 4 weeks (that is no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). CRi is defined as hematologic complete remission with incomplete hematologic recovery and meeting all criteria for CR except platelet count and/or ANC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of MRD-Negative CR</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>MRD is defined as the percentage of participants achieving CR who are MRD-negative. MRD negativity: &lt;=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. Relapse from CR: Reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MRD-Negative CR</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Duration of MRD-negative CR is defined as interval between the first assessment at which the criteria for MRD-negative CR are met until the earliest date at which loss of MRD negativity or relapse from CR occurs. MRD negativity (MR4): &lt;=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. Relapse from CR: Reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Duration of CR is defined as interval between the first assessment at which the criteria for CR are met until the earliest date at which relapse from CR occurs. CR is defined as meeting all the following for at least 4 weeks (that is no recurrence): 1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L). Relapse from CR: Reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Every year after 3 years up to 5 years</time_frame>
    <description>Time to treatment failure is defined as time to being off study randomized treatment (except for hematopoietic stem cell transplantation [HSCT] without loss of MRD-negative CR) due to both safety and/or loss of efficacy benefit reasons. MRD-negative CR is achieved when a participant meets the criteria for both MRD negativity and CR. MRD-negativity: &lt;=0.01% BCR-ABL1/ABL1, or undetectable BCR-ABL1 transcripts in cDNA with &gt;=10,000 ABL1 transcripts. CR: meeting all the following for at least 4 weeks (that is no recurrence):1. No circulating blasts and &lt;5% blasts in the BM. 2. Normal maturation of all cellular components in the BM. 3. No extramedullary disease (CNS involvement, lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass). 4. ANC &gt;1000/mcL (or &gt;1.0*10^9/L). 5. Platelets &gt;100,000/mcL (or &gt;100*10^9/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with MR4.5 Including Best Response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>MR4.5 is molecular response 4.5-log reduction (&lt;=0.0032% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=32,000 ABL1 transcripts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of MR4.5</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Duration of MR4.5 is defined as interval between the first assessment at which the criteria for MR4.5 are met until the earliest date at which loss of MR4.5 occurs. MR4.5 is molecular response 4.5-log reduction (&lt;=0.0032% BCR-ABL1/ABL1), or undetectable BCR-ABL1 transcripts in cDNA with &gt;=32,000 ABL1 transcripts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of On-Study Participants with Overall Survival (OS)</measure>
    <time_frame>Every year after 3 years up to 5 years</time_frame>
    <description>On-study participants with or without HSCT will be evaluated. OS is defined as the interval between the first dose date of study drug and death due to any cause, censored at the last contact date when the participant was alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of On-Study Participants with Relapse From CR</measure>
    <time_frame>Every year after 3 years up to 5 years</time_frame>
    <description>On-study participants with or without HSCT will be evaluated. Relapse from CR is defined as reappearance of blasts in the blood or BM (&gt;=5%) or in any extramedullary site after a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is defined as interval between the first dose date of study drug and death due to any cause, censored at the last contact date when the participant was alive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Lymphoblastic Leukemia, Acute, Adult</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <condition>Leukemia, Lymphoblastic</condition>
  <condition>Ph1 Chromosome</condition>
  <condition>Leukemia, Lymphoblastic, Acute, Philadelphia-Positive</condition>
  <arm_group>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ponatinib 30 mg, tablets, orally, once daily (QD), along with vincristine 1.4 mg/m^2 (maximum [max] 2 mg) intravenous(IV), on Days 1 and 14 and dexamethasone 40 mg(&lt;60 years [yrs]) and 20 mg (&gt;=60 yrs), orally, once on Days 1 to 4 and Days 11 to 14 in 28-day cycle for up to 3 cycles in induction phase followed by ponatinib last dose of induction phase tablets, orally, QD, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour IV infusion (&lt;=60 yrs) and 250 mg/m^2 every 12 hours (&gt;60 yrs), IV on Days 1, 3, and 5 of 28-day even cycles(Cycles 2, 4, and 6) and methotrexate, 1000 mg/m^2 (&lt;=60 yrs) and 250 mg/m^2 (&gt;60 yrs), IV infusion, on Day 1 of 28-day odd cycles(Cycle 1, 3, and 5) in consolidation phase followed by ponatinib last dose of consolidation phase, tablets, orally, QD, along with vincristine 1.4 mg/m^2,(max 2 mg) IV, on Day 1 and prednisone 200 mg (&lt;60 yrs), 100 mg (&gt;=60-69 yrs) and 50 mg(&gt;=70 yrs) on Days 1 to 5 in 28-day cycle for up to 11 cycles in maintenance phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imatinib 600 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2 (max 2 mg) IV, on Days 1 and 14 and dexamethasone 40 mg (&lt;60 yrs) and 20 mg (&gt;=60 yrs), orally, once on Days 1 through 4 and Days 11 through 14 in each 28-day cycle for up to 3 cycles in induction phase followed by imatinib 600 mg, tablets, orally, once daily, along with cytarabine, 1000 mg/m^2 every 12 hours as a 2-hour-IV infusion (&lt;=60 yrs) and 250 mg/m^2 every 12 hours (&gt;60 yrs), IV on Days 1, 3, and 5 of each 28-day even cycles (Cycles 2, 4, and 6) and methotrexate, 1000 mg/m^2 (&lt;=60 yrs) and 250 mg/m^2 (&gt;60 yrs), IV infusion, on Day 1 of each 28-day odd cycles (Cycle 1, 3, and 5) in consolidation phase followed by imatinib 600 mg, tablets, orally, once daily, along with vincristine 1.4 mg/m^2, (max 2 mg) IV, on Day 1 and prednisone 200 mg (&lt;60 yrs), 100 mg (&gt;=60-69 yrs) and 50 mg (&gt;=70 yrs) on Days 1 through 5 in each 28-day cycle for up to 11 cycles in maintenance phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Ponatinib Tablets.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <other_name>Iclusig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Imatinib Tablets.</description>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
    <other_name>Gleevec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine IV injection.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone Tablets.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine IV infusion.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate IV infusion.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone Tablets.</description>
    <arm_group_label>Cohort A: Ponatinib 30 milligram (mg)</arm_group_label>
    <arm_group_label>Cohort B: Imatinib 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL, as
             defined by the 2017 national comprehensive cancer network (NCCN) guidelines.

          2. Molecular assessment of BCR-ABL1 must demonstrate the presence of a p190 (that is
             e1a2) or p210 (that is, e13a2 or e14a2 [also known as b2a2 or b3a2]) transcript type.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of &lt;=2.

        Exclusion Criteria:

          1. With a history or current diagnosis of chronic phase, accelerated phase, or blast
             phase chronic myeloid leukemia (CML).

          2. Prior/current treatment with any systemic anticancer therapy (including but not
             limited to any tyrosine kinase inhibitor [TKI]) and/or radiotherapy for ALL, with the
             exception of an optional prephase therapy or chemotherapy induction (no more than 1
             cycle), which should be discussed with the sponsor's medical monitor/designee.

          3. Currently taking drugs that are known to have a risk of causing prolonged corrected QT
             (QTc) or torsades de pointes (TdP) (unless these can be changed to acceptable
             alternatives or discontinued).

          4. Taking any medications or herbal supplements that are known to be strong inhibitors or
             strong inducers of cytochrome P450 (CYP)3A4 within at least 14 days before the first
             dose of study drug.

          5. Uncontrolled active serious infection that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to this protocol.

          6. Major surgery within 28 days before randomization (minor surgical procedures such as
             catheter placement or BM biopsy are not exclusionary criteria).

          7. Known human immunodeficiency virus (HIV) seropositivity, known active hepatitis B or C
             infection.

          8. History of acute pancreatitis within 1 year of study screening or history of chronic
             pancreatitis.

          9. Uncontrolled hypertriglyceridemia (triglycerides &gt;450 milligram per deciliter
             [mg/dL]).

         10. Diagnosed and treated for another malignancy within 5 years before randomization or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type
             are not excluded if they have undergone complete resection.

         11. History or presence of clinically relevant CNS pathology such as epilepsy, childhood
             or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia,
             Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.

         12. Clinical manifestations of CNS or extramedullary involvement with ALL.

         13. Autoimmune disease with potential CNS involvement.

         14. Known significant neuropathy of Grade &gt;=2 severity.

         15. Clinically significant, uncontrolled, or active cardiovascular, cerebrovascular, or
             peripheral vascular disease, or history of or active venous thrombotic/embolic event
             (VTE) disease.

         16. Have a significant bleeding disorder unrelated to ALL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-866-835-2233</phone>
    <email>globaloncologymedinfo@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope - Duarte</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Blood &amp; Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Centro Medico de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5014KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz Elisabethinen</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus Wiener Gebietskrankenkasse</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minsk Scientific and Practical Center of Surgery, Transplantation and Haematology</name>
      <address>
        <city>Minsk</city>
        <zip>220045</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Center of Children's Oncology, Hematology and Immunology</name>
      <address>
        <city>Minsk</city>
        <zip>223053</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Rafael-Monte Tabor</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eurolatino Juiz de Fora Pesquisas Medicas</name>
      <address>
        <city>Juiz De Fora</city>
        <state>Minas Gerais</state>
        <zip>36033-318</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital da Cidade</name>
      <address>
        <city>Passo Fundo</city>
        <state>RIO Grande DO SUL</state>
        <zip>99010-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hemocentro Campinas Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>SAO Paulo</state>
        <zip>130383-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacao Doutor Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <state>SAO Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Riberao Preto da Universidade de Sao Paulo</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SAO Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HEMORIO Instituto Estadual de Hematologia</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacao Antonio Prudente - A.C.Camargo Cancer Center</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Saint Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <state>Sofiya</state>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Charles-LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsingin ja Uudenmaan sairaanhoitopiiri</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oulun Yliopistollinen Sairaala</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <state>Ile-de-france</state>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <state>PAYS DE LA Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <state>Rhone-alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evaggelismos General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens G. Gennimatas</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki George Papanikolaou</name>
      <address>
        <city>Thessaloniki</city>
        <state>Macedoni</state>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras Panagia I Voithia</name>
      <address>
        <city>Patra</city>
        <state>Peloponnese</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forli-cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>Monza E Brianza</state>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Reggio Nella Emilia</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Universitario San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda USL della Romagna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Number 1 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie - Oddzial w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurs</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovsk</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Center for Hematology, Dept. of Hematology/Oncology and BMT</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almazov Federal North-West Medical Research Centre of Department of Health of Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia Badalona - Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Cataluna</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Taichung CITY</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <state>Tainan CITY</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tp Fakultesi</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ponatinib</keyword>
  <keyword>Imatinib mesylate</keyword>
  <keyword>Bcr-Abl Tyrosine Kinase</keyword>
  <keyword>Bcr-abl fusion proteins</keyword>
  <keyword>Iclusig</keyword>
  <keyword>Gleevec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

